{"id":"https://genegraph.clinicalgenome.org/r/8f3ce5af-5df1-493d-8a79-65bbe053c0ffv1.0","type":"EvidenceStrengthAssertion","dc:description":"The *DNAI1* gene was first reported in relation to primary ciliary dyskinesia in 1999 (Pennarun et al, PMID: 10577904). The specific disease entity, primary ciliary dyskinesia 1 (MONDO:0009484, OMIM #244400), is one of at least 45 different primary ciliary dyskinesias distinguished by a single monogenic cause. Affected patients can have onset of symptoms at birth but can also be diagnosed at least as late as during the 3rd decade of life (PMID: 11713099). Frequent features among well-characterized patients are neonatal respiratory distress, sinusitis, otitis media, bronchiectasis, and decreased nasal nitric oxide. Approximately 50% of cases exhibit situs inversus or another form of heterotaxy. Biopsies of the airway epithelium show ciliary ultrastructure with an absence of outer dynein arms and to a lesser degree absence of inner dynein arms. Cilia are largely or completely immotile. Adult patients can exhibit infertility.\n \nThis curation has scored thirteen suspected pathogenic *DNAI1* variants (three missense, three frameshift, four nonsense, and three disrupting splicing), which were collectively reported in thirteen probands in six publications (PMID: 10577904, PMID: 21143860, PMID: 16858015, PMID: 11713099, PMID: 21270641, PMID: 29363216). All of the probands harbored biallelic variants confirmed to be present in trans. No probands were reported to be from consanguineous parents, but two harbored *DNAI1* variants in the homozygous state, while the other eleven probands were compound heterozygous. The molecular mechanism appears to be biallelic loss-of-function with an autosomal recessive mode of inheritance, characterized in at least some cases by variants predicted to trigger the absence of a gene product. More genetic evidence was available (PMID: 11231901, PMID: 21143860, PMID: 16858015, PMID: 11713099) but was not included as the maximum for this category of evidence had already been reached. Large families with segregation data were not found for inclusion in this gene curation. Please note that the genetic evidence scored in this curation has relied heavily on the best-characterized *DNAI1* variants from the literature, while an urgent need remains for additional published data to evaluate the pathogenicity of many other emerging variants.\n \nThis gene-disease relationship is also supported by experimental evidence that high levels of *DNAI1* expression in humans are specific to tissues known to harbor multi-ciliated cells, particularly the testis, pituitary gland, fallopian tube, lung, and endocervix (PMID: 23715323). Biochemical studies of the *Chlamydomonas* ortholog of DNAI1 indicate that the protein product is an intermediate dynein chain positioned at the base of the alpha-beta dimer of the outer dynein arms (PMID: 2147183). Its direct interaction with alpha-tubulin (PMID: 1827120) indicates that it may function to link the outer dynein arms with axonemal microtubules, consistent with the ultrastructural defects characteristic of the human patients. The protein also interacts with the *Chlamydomonas* ortholog of DNAI2 (2147183), a related intermediate dynein chain that is associated in humans with primary ciliary dyskinesia 9. Human patient phenotypes such as ciliary immotility and absence of outer dynein arms are recapitulated by *Chlamydomonas* (PMID: 7698982) and other cellular models (PMID: 32823934) of DNAI1 loss of function. More complex patient phenotypes are recapitulated by a combination of conventional (PMID: 24306492) and conditional (PMID: 19675306) mouse models of *Dnai1* loss of function.\n \nIn summary, *DNAI1* is definitively associated with primary ciliary dyskinesia 1. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a Definitive classification. This classification was approved by the ClinGen Motile Ciliopathy GCEP on June 9th, 2022 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/8f3ce5af-5df1-493d-8a79-65bbe053c0ff","GCISnapshot":"https://genegraph.clinicalgenome.org/r/396be572-5b2c-4859-90dd-434a91c1ce96","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/396be572-5b2c-4859-90dd-434a91c1ce96_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10102","date":"2022-06-30T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/396be572-5b2c-4859-90dd-434a91c1ce96_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10102","date":"2022-06-30T17:42:17.665Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/396be572-5b2c-4859-90dd-434a91c1ce96_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/396be572-5b2c-4859-90dd-434a91c1ce96_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d58365e5-3225-42c8-8cd6-0f31410ad0b5","type":"EvidenceLine","dc:description":"The mouse model partially recapitulated the human patient phenotype at both the cellular and organ levels. Down-scoring was not performed because some typical PCD phenotypes that were missing from the model (hydrocephalus, situs abnormalities) were not expected because the model has inducible loss of DNAI1 function triggered late in the process of development.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c0d5e30f-69da-40c7-8633-f16f65699d00","type":"Finding","dc:description":"The mice did not develop lung disease. However, the tamoxifen treatment of cultured tracheal epithelial cells triggered near-complete inhibition of ciliary beating (Figure 3C) and loss of outer dynein arms (Figure 5). The mice exhibited an impaired nasal mucociliary clearance phenotype (Figure 6), accompanied by severe rhinosinusitis (Figure 7), which were collectively reminiscent of the human patients at both the cellular and organ levels. It is important to note that hydrocephalus, situs abnormalities, and other developmental phenotypes are not expected in this inducible model.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19675306","rdfs:label":"Dnaic1 inducible deletion mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7db14647-02bb-4825-938b-8bdb7a123b3c","type":"EvidenceLine","dc:description":"The model recapitulates the human patients' defects in axonemal ultrastructure and ciliary/flagellar motility, but has been down-scored due to the model system's inability to recreate organism-level phenotypes of the human patients.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3b36f5c7-7d7c-4e9c-bf33-4c4d7a47ee09","type":"Finding","dc:description":"The Chlamydomonas mutants are unable to model the organism-level phenotypes of the human patients, but recapitulate the defects in axonemal ultrastructure (absence of outer dynein arms, Figure 9) and ciliary/flagellar motility (slow and jerky swimming, described in the text) characteristic of the human disease state at the cellular level.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7698982","rdfs:label":"Chlamydomonas model of DNAI loss-of-function","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/cc447098-e9c3-4e28-8910-c33cad8265c5","type":"EvidenceLine","dc:description":"While these mice successfully model the human patient phenotype at the cellular and organismal levels, this evidence has been down-scored to avoid overlap with the previously scored mouse model from PMID: 19675306. Essentially this model is being scored for hydrocephalus and situs abnormalities / heterotaxy alone, which were absent from the other model.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7099e6d7-9076-4052-bc09-f41e544059d1","type":"Finding","dc:description":"The hydrocephalus and associated early death are both consistent with the ciliary defect, while the situs inversus totalis / heterotaxy phenotype matches the human phenotype. All of these phenotypes in the Bishu mouse complement the Dnaic1 deletion model reported in PMID: 19675306, which harbors a conditional deletion activated by tamoxifen treatment after weaning, and therefore did not develop these early PCD features. This model also recapitulates both the immotile cilia and absent outer dynein arms observed in the other model and in the human patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24306492","rdfs:label":"Bishu mouse harbors homozygous splicing variant in Dnaic1","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/76182bd3-8759-4679-8086-1e3c67eb4b5a","type":"EvidenceLine","dc:description":"This experiment was down-scored out of concern that its value in describing the cellular level of the disease mechanism might partially overlap with the previously scored mouse model.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a9d3cf46-42b7-4116-9379-c7d489c43f89","type":"Finding","dc:description":"Although knockdown of the murine Dnaic1 gene did not affect the generation or length of the cilia, half of ciliated cells were rendered immotile (Table 1), while some of the remaining motile cilia showed dyskinetic motion (Supplementary Videos S6 and S7). This matches the human patient phenotype of immotile cilia, and is indirectly related to molecular phenotypes such as absence of outer dynein arms and organ-level phenotypes such as recurrent bronchitis and sinusitis.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32823934","rdfs:label":"Dnaic1 knockdown in mouse ciliated tracheal epithelium","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/396be572-5b2c-4859-90dd-434a91c1ce96_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f1fa365c-c8d0-4be9-9fde-36ad41b635d9","type":"EvidenceLine","dc:description":"The function of DNAI1 as a dynein intermediate chain is consistent with the cellular defects of the human patients.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a66e0a44-2dbb-4a9a-866c-d15d52633cf0","type":"Finding","dc:description":"Evidence that the DNAI1 ortholog IC78 binds to outer dynein complexes (Figure 2) and localizes to the base of the alpha-beta dimer of the outer dynein arms (Figures 3 and 4) is consistent with the defects in outer dynein arm positioning observed in the patient disease state.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2147183","rdfs:label":"DNAI1 functions in outer dynein arm assembly","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/137cd41d-8a15-4fbe-8806-2954ced3b57c","type":"EvidenceLine","dc:description":"DNAI1 physically interacts with another dynein chain implicated in PCD. Their localization to the base of the outer dynein arm complex is consistent with the absence of outer dynein arms in the respiratory cells of DNAI1-deficient and DNAI2-deficient patients.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c236491-0b61-46e9-9c75-3b22b6aaace1","type":"Finding","dc:description":"DNAI2 has been asserted to be associated with primary ciliary dyskinesia 9, with or without situs inversus (MIM#:612444, MONDO:0012906). Its interaction with DNAI1 was established through the observation that an antibody-based pull-down of the Chlamydomonas ortholog of DNAI2 (IC69 protein) also isolates the DNAI1 ortholog (IC78).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2147183","rdfs:label":"The Chlamydomonas orthologs of DNAI1 and DNAI2 interact.","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6a299774-6f42-4651-8bcd-1e33e710767b","type":"EvidenceLine","dc:description":"The expression profile of DNAI1 across multiple tissues shows highly specific expression in several tissues that contain multi-ciliated cells.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7b1086bd-1e36-4139-b11d-41e38b66599c","type":"Finding","dc:description":"Human RNA-seq data from the GTEx portal (PMID: 23715323) show high DNAI1 expression in testis, pituitary gland, fallopian tube, lung, and endocervical tissues. All of these tissues contain multi-ciliated cells, consistent with a role for DNAI1 in ciliary function. These data are corroborated by Northern expression data from PMID: 10577904.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23715323","rdfs:label":"DNAI1 is highly expressed in multi-ciliated tissues","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5.5},{"id":"https://genegraph.clinicalgenome.org/r/396be572-5b2c-4859-90dd-434a91c1ce96_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/412faefc-0ae8-44c7-8a3d-3978313dba69_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/570e7568-aaf5-4907-ad58-bbadd4f5675d","type":"EvidenceLine","dc:description":"The variant has been conservatively up-scored based on the functional evidence indicating that it triggers the omission of an exon encoding a large region near the C-terminus of the protein product.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/570e7568-aaf5-4907-ad58-bbadd4f5675d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_012144.4(DNAI1):c.2001+1G>A disrupts a canonical splicing site in intron 19 that has been confirmed by in vitro splicing assay to cause in-frame deletion of exon 19 (which encodes p.Ala607_Lys667del, approximately 10% of the protein product).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/570e7568-aaf5-4907-ad58-bbadd4f5675d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/2f62674a-a7f7-41af-ae89-c6894e8f47ea","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.2001+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA345043"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d2663c27-2a36-4ec5-a97f-2685614456da","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1307G>A (p.Trp436Ter) is a nonsense variant in exon 13 of 20, and is predicted to trigger nonsense-mediated decay or at least disrupt the C-terminal 27% of the protein product. It has been down-scored to reflect the genotyping method (Sanger sequencing-based, focusing on the DNAI1 candidate locus).","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2663c27-2a36-4ec5-a97f-2685614456da_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/e0604ea4-f2ba-4d02-adca-6707e00f3b7d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.1307G>A (p.Trp436Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5034342"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/412faefc-0ae8-44c7-8a3d-3978313dba69","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","rdfs:label":"Zariwala_2006_D32X1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":10,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/2f62674a-a7f7-41af-ae89-c6894e8f47ea"},{"id":"https://genegraph.clinicalgenome.org/r/e0604ea4-f2ba-4d02-adca-6707e00f3b7d"}],"detectionMethod":"The patient was genotyped at the DNAI1 locus by Sanger sequencing of PCR products from the 20 exons and associated flanking regions of the DNAI1 locus.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has been diagnosed with primary ciliary dyskinesia without Kartagener syndrome (implying absence of dextrocardia). Analysis of ciliary ultrastructure showed an outer dynein arm defect.","phenotypes":["obo:HP_0000246","obo:HP_0000388","obo:HP_0002110"],"previousTesting":false,"previousTestingDescription":"Previous testing was limited to clinical characterization of PCD.","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/570e7568-aaf5-4907-ad58-bbadd4f5675d_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/d2663c27-2a36-4ec5-a97f-2685614456da_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/c94cde78-a80e-4985-93ec-72a346c596cd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3679a4b9-e118-4a98-b225-c9fb133e736c","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1222G>A (p.Val408Met) is a missense variant in exon 13, which harbors a number of suspected pathogenic variants, but does not have experimental evidence of gene impact.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3679a4b9-e118-4a98-b225-c9fb133e736c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/8670fc87-5c1b-448f-b52a-51bb25ac6a15","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.1222G>A (p.Val408Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA240119"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/6f868d50-1eae-43b3-ace5-d86646b19cce","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1212T>G (p.Tyr404Ter) is a nonsense variant in exon 13 of 20 that is predicted to trigger nonsense-mediated decay or at least truncate the C-terminal 33% of the protein product. Down-scoring was performed to reflect the genotyping by Sanger sequencing of the DNAI1 candidate gene alone.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6f868d50-1eae-43b3-ace5-d86646b19cce_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/45936e6d-21d5-4772-825b-859b68a927e6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.1212T>G (p.Tyr404Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/952542"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c94cde78-a80e-4985-93ec-72a346c596cd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","rdfs:label":"Zariwala_2006_Proband_630","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":18,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/45936e6d-21d5-4772-825b-859b68a927e6"},{"id":"https://genegraph.clinicalgenome.org/r/8670fc87-5c1b-448f-b52a-51bb25ac6a15"}],"detectionMethod":"Sanger sequencing of PCR products from the 20 exons and associated flanking regions of the DNAI1 locus","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has been diagnosed with primary ciliary dyskinesia with dextrocardia. Analysis of ciliary ultrastructure showed an outer dynein arm defect.","phenotypes":["obo:HP_0000388","obo:HP_0000246","obo:HP_0002643","obo:HP_0001651"],"previousTesting":false,"previousTestingDescription":"Previous testing was limited to clinical characterization of PCD.","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/3679a4b9-e118-4a98-b225-c9fb133e736c_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6f868d50-1eae-43b3-ace5-d86646b19cce_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/c81b471b-192a-4dda-bf5a-08f64d1d937c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24cabf23-3fe6-4688-bc6a-acf7a9918f68","type":"EvidenceLine","dc:description":"The NM_012144.4:c.1925_1926dup (p.Ile643ProfsTer48) variant is a frameshift variant in exon 19 of 20, predicted to trigger nonsense-mediated decay or to at least truncate the C-terminal 8% of the protein product. The variant has been down-scored to reflect the genotyping method limited to Sanger sequencing of the candidate DNAI1 locus.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24cabf23-3fe6-4688-bc6a-acf7a9918f68_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/e93af184-14d3-4e5b-b15e-ae4ae60934d0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.1925_1926dup (p.Ile643ProfsTer48)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573106194"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ee3d644f-daae-4489-ac14-e839951a439b","type":"EvidenceLine","dc:description":"The variant has been up-scored for the experimental evidence of a null effect on the gene, but down-scored for its identification as a founder variant (PMID: 16858015) that has a high frequency in the control population and has already been scored in a separate proband (PMID: 10577904).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee3d644f-daae-4489-ac14-e839951a439b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The NM_012144.4(DNAI1):c.48+2dup variant near the junction of exon 1 and intron 1 creates a cryptic splice donor site that triggers a 132bp in-frame insertion of sequence from intron 1 into the transcript (Fig. 7E). Please note the high frequency of this paternal allele in the control population from gnomAD.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ee3d644f-daae-4489-ac14-e839951a439b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.48+2dup","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340437"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c81b471b-192a-4dda-bf5a-08f64d1d937c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","rdfs:label":"Zariwala_2006_Proband_749","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":8,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},{"id":"https://genegraph.clinicalgenome.org/r/e93af184-14d3-4e5b-b15e-ae4ae60934d0"}],"detectionMethod":"The patient was genotyped at the DNAI1 locus by Sanger sequencing of PCR products from the 20 exons and associated flanking regions of the DNAI1 locus.","ethnicity":{"id":"cg:HispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has been diagnosed with primary ciliary dyskinesia without Kartagener syndrome (implying absence of dextrocardia). Analysis of ciliary ultrastructure showed an outer dynein arm defect.","phenotypes":["obo:HP_0033036","obo:HP_0002110","obo:HP_0000388","obo:HP_0000246"],"previousTesting":false,"previousTestingDescription":"Previous testing was limited to clinical characterization of PCD.","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/ee3d644f-daae-4489-ac14-e839951a439b_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/24cabf23-3fe6-4688-bc6a-acf7a9918f68_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/04305536-31d6-47dc-a397-3cdad24ebe1b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/accecda7-684d-40c4-bcb5-d92724a9e8a4","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1612G>A (p.Ala538Thr) is a missense variant in exon 17 without experimental evidence of gene impact. It is a recurring variant detected in 5 apparently unrelated probands in this study and 2 more in PMID: 16858015, including on 2 different haplotypes. However, it has not been upscored due to its relatively high allele frequency in the control population.","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/accecda7-684d-40c4-bcb5-d92724a9e8a4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21143860","allele":{"id":"https://genegraph.clinicalgenome.org/r/6189319f-6cf8-4a7a-a8c1-934867a8cd96","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.1612G>A (p.Ala538Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/583106"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/04305536-31d6-47dc-a397-3cdad24ebe1b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21143860","rdfs:label":"ZiÄ™tkiewicz_2010_Family_151_Patient_555","allele":{"id":"https://genegraph.clinicalgenome.org/r/6189319f-6cf8-4a7a-a8c1-934867a8cd96"},"detectionMethod":"The patient was genotyped at the DNAI1 locus by SSCP of PCR products followed by Sanger sequencing. Multiplex ligation-dependent probe amplification analysis was subsequently performed to detect large exonic deletions.","firstTestingMethod":"SSCP","phenotypeFreeText":"The patient has been diagnosed with primary ciliary dyskinesia. Of cilia examined by electron microscope, 80% had outer or inner dynein arm defect, while 4% had a microtubule organization defect.","phenotypes":["obo:HP_0012257","obo:HP_0033036","obo:HP_0012256","obo:HP_0012263"],"previousTestingDescription":"Previous testing was limited to clinical characterization of PCD.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/accecda7-684d-40c4-bcb5-d92724a9e8a4_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/0834178c-fed1-42cb-a4a9-467fe542d026_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ee28fb5-55df-4a9f-8405-721708964534","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1703G>C (p.Trp568Ser) is a missense variant in exon 17 and does not have evidence of gene impact.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ee28fb5-55df-4a9f-8405-721708964534_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11713099","allele":{"id":"https://genegraph.clinicalgenome.org/r/f987eb1d-de71-4c3b-8341-40743fe952e1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.1703G>C (p.Trp568Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5034499"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e76f4cc0-02df-45c9-8761-24f565af4133","type":"EvidenceLine","dc:description":"This variant has been up-scored due to evidence of gene impact at the mRNA level, but partially down-scored due to its identification as a high frequency founder variant (PMID: 16858015).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e76f4cc0-02df-45c9-8761-24f565af4133_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The NM_012144.4(DNAI1):c.48+2dup variant near the junction of exon 1 and intron 1 creates a cryptic splice donor site that triggers a 132bp in-frame insertion of sequence from intron 1 into the transcript (Fig. 7E from PMID: 10577904).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e76f4cc0-02df-45c9-8761-24f565af4133_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11713099","allele":{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0834178c-fed1-42cb-a4a9-467fe542d026","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11713099","rdfs:label":"Zariwala_2001_Family_5_Patient_III-3","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":1,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},{"id":"https://genegraph.clinicalgenome.org/r/f987eb1d-de71-4c3b-8341-40743fe952e1"}],"detectionMethod":"The patient was genotyped by a combination of linkage analysis to the DNAI1 locus (using 2 SNPs), Sanger sequencing of PCR products from the 20 exons and associated flanking regions of the DNAI1 locus, and genotyping of family members by restriction enzyme digest of DNAI1 PCR products (for the maternal variant) or denaturing HPLC (for the paternal variant) to test for segregation.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has been diagnosed with primary ciliary dyskinesia.","phenotypes":["obo:HP_0005425","obo:HP_0002643","obo:HP_0011620","obo:HP_0012256","obo:HP_0012257","obo:HP_0410018"],"previousTesting":true,"previousTestingDescription":"Previous testing was linkage analysis to the DNAI1 locus (using 2 SNPs) among a cohort of PCD subjects.","secondTestingMethod":"Restriction digest","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/e76f4cc0-02df-45c9-8761-24f565af4133_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/7ee28fb5-55df-4a9f-8405-721708964534_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/0cbb0958-89e0-4ab2-ad0c-ce048f8f12cc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f54b0947-0e10-4183-a8ec-3e43cbc6dc23","type":"EvidenceLine","dc:description":"This variant has been up-scored due to evidence of gene impact at the mRNA level, but partially down-scored due to its identification as a high frequency founder variant (PMID: 16858015).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f54b0947-0e10-4183-a8ec-3e43cbc6dc23_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The NM_012144.4(DNAI1):c.48+2dup variant near the junction of exon 1 and intron 1 creates a cryptic splice donor site that triggers a 132bp in-frame insertion of sequence from intron 1 into the transcript (Fig. 7E in PMID: 10577904).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/f54b0947-0e10-4183-a8ec-3e43cbc6dc23_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11713099","allele":{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1c4f433b-10b1-4634-acc8-e738c9e16ce3","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1704G>A (p.Trp568Ter) is a nonsense variant in exon 17 that is predicted to trigger nonsense-mediated decay or at least truncate the C-terminal 19% of the protein product. It has been partially down-scored due to the genotyping method (Sanger sequencing focused on the DNAI1 candidate gene).","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c4f433b-10b1-4634-acc8-e738c9e16ce3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11713099","allele":{"id":"https://genegraph.clinicalgenome.org/r/e61a621d-a231-4394-8df4-d558d8e9cc72","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.1704G>A (p.Trp568Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373263895"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0cbb0958-89e0-4ab2-ad0c-ce048f8f12cc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11713099","rdfs:label":"Zariwala_2001_Family_16_Patient_II-2","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":25,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/e61a621d-a231-4394-8df4-d558d8e9cc72"},{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"}],"detectionMethod":"The patient was genotyped by a combination of linkage analysis to the DNAI1 locus (using 2 SNPs), Sanger sequencing of PCR products from the 20 exons and associated flanking regions of the DNAI1 locus, and genotyping of family members by restriction enzyme digest of DNAI1 PCR products (for the maternal variant) or denaturing HPLC (for the paternal variant) to test for segregation.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"\n\nCaseHPOFreeText: The patient has been diagnosed with primary ciliary dyskinesia, and conceived children using artificial insemination of his sperm. Sputum microbiology included P. aeruginosa.","phenotypes":["obo:HP_0002110","obo:HP_0005425","obo:HP_0002643","obo:HP_0410018","obo:HP_0012256"],"previousTesting":true,"previousTestingDescription":"Previous testing was linkage analysis to the DNAI1 locus (using 2 SNPs) among a cohort of PCD subjects.","secondTestingMethod":"Restriction digest","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/1c4f433b-10b1-4634-acc8-e738c9e16ce3_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f54b0947-0e10-4183-a8ec-3e43cbc6dc23_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/aa192f87-edb8-4b81-8234-b4a2c4f41309_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/92403f65-a690-40fa-9ba6-8f1ce02c0933","type":"EvidenceLine","dc:description":"The variant has been up-scored for the evidence of impact at the mRNA level, but down-scored for homozygosity, characterization as a high-frequency founder variant in this study, and having been scored at full strength in other probands.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/92403f65-a690-40fa-9ba6-8f1ce02c0933_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The NM_012144.4(DNAI1):c.48+2dup variant near the junction of exon 1 and intron 1 creates a cryptic splice donor site that triggers a 132bp in-frame insertion of sequence from intron 1 into the transcript (Fig. 7E from PMID: 10577904).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/92403f65-a690-40fa-9ba6-8f1ce02c0933_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/aa192f87-edb8-4b81-8234-b4a2c4f41309","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","rdfs:label":"Zariwala_2006_Patient_PCD552","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":13,"allele":{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},"detectionMethod":"The patient was genotyped at the DNAI1 locus by Sanger sequencing of PCR products from the 20 exons and associated flanking regions of the DNAI1 locus.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has been diagnosed with primary ciliary dyskinesia without Kartagener syndrome (implying absence of dextrocardia). Analysis of ciliary ultrastructure showed an outer dynein arm defect.","phenotypes":["obo:HP_0000246","obo:HP_0002110","obo:HP_0002643","obo:HP_0000388"],"previousTesting":false,"previousTestingDescription":"Previous testing was limited to clinical characterization of PCD.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/92403f65-a690-40fa-9ba6-8f1ce02c0933_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ae8e24de-393e-46fe-97ba-8fe136c5ca9a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17229ab8-6ec1-405c-9d11-fc1379762f18","type":"EvidenceLine","dc:description":"The aberrant insertion of 132bp of intronic sequence into the transcript has been confirmed by PCR from the cDNA of the patient and his father. Up-scoring was performed conservatively since genotyping was limited to the DNAI1 candidate locus alone.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17229ab8-6ec1-405c-9d11-fc1379762f18_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The NM_012144.4(DNAI1):c.48+2dup variant near the junction of exon 1 and intron 1 creates a cryptic splice donor site that triggers a 132bp in-frame insertion of sequence from intron 1 into the transcript (Fig. 7E). Please note the high frequency of this paternal allele in the control population from gnomAD.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/17229ab8-6ec1-405c-9d11-fc1379762f18_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10577904","allele":{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/838fffd1-8bda-402d-97d9-060f319c322a","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.282_283insAATA (p.Gly95fs) is a frameshift variant in exon 5 of 20, predicted to either trigger nonsense-mediated decay or disrupt the C-terminal 87% of the protein product. Down-scoring was performed since genotyping was limited to the DNAI1 candidate locus alone.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/838fffd1-8bda-402d-97d9-060f319c322a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10577904","allele":{"id":"https://genegraph.clinicalgenome.org/r/9ccf847e-18b8-40c1-a7ce-e2c215810fac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.282_283insAATA (p.Gly95fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA253532"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ae8e24de-393e-46fe-97ba-8fe136c5ca9a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10577904","rdfs:label":"Pennarun_1999_Patient_II-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":9,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},{"id":"https://genegraph.clinicalgenome.org/r/9ccf847e-18b8-40c1-a7ce-e2c215810fac"}],"detectionMethod":"The patient and controls were genotyped by SSCP of PCR products from the DNAI1 locus, followed by Sanger sequencing to identify the variants in the PCR products from exon 1 / intron 1 and exon 5. The two variants have been confirmed to be in trans by parental genotyping, which was based on restriction enzyme digest of PCR products (with either VspI or HpaI).","firstTestingMethod":"SSCP","phenotypeFreeText":"No ciliary beating frequency was observed. Bronchitis episodes led to severe segmental atelectasis, which was treated with partial lobectomy.","phenotypes":["obo:HP_0011109","obo:HP_0012263","obo:HP_0100750","obo:HP_0002837","obo:HP_0012256","obo:HP_0031353"],"previousTesting":false,"previousTestingDescription":"Previous testing was limited to clinical characterization of PCD.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/838fffd1-8bda-402d-97d9-060f319c322a_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/17229ab8-6ec1-405c-9d11-fc1379762f18_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/f678a3a6-34a1-418d-90f4-5f692cf32079_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/98b6c495-10fb-498f-92a9-2cb04e38d3e0","type":"EvidenceLine","dc:description":"The NM_012144.4(DNAI1):c.565_566del (p.Leu188_Thr189insTer)) variant is a frameshift variant in exon 5 of 20 that is predicted to trigger nonsense-mediated decay or at least truncate the C-terminal 73% of the protein product. Moderate down-scoring has been performed to account for the uncertainty about whether this proband was one of those whose family members were available for genotyping to identify the two variants as in trans.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/98b6c495-10fb-498f-92a9-2cb04e38d3e0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29363216","allele":{"id":"https://genegraph.clinicalgenome.org/r/6bdd4757-0be0-4f8b-953f-c29e01591926","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.565_566del (p.Leu188_Thr189insTer)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1184556"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/baffc33b-cbaf-493c-b778-6754335fd0d5","type":"EvidenceLine","dc:description":"This variant has been up-scored due to evidence of gene impact at the mRNA level, but partially down-scored due to its identification as a high frequency founder variant (PMID: 16858015).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/baffc33b-cbaf-493c-b778-6754335fd0d5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The NM_012144.4(DNAI1):c.48+2dup variant near the junction of exon 1 and intron 1 creates a cryptic splice donor site that triggers a 132bp in-frame insertion of sequence from intron 1 into the transcript (Fig. 7E from PMID: 11713099). Please note the high frequency of this paternal allele in the control population from gnomAD.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/baffc33b-cbaf-493c-b778-6754335fd0d5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29363216","allele":{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f678a3a6-34a1-418d-90f4-5f692cf32079","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29363216","rdfs:label":"Paff_2018_Patient_PCD-8170","allele":[{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},{"id":"https://genegraph.clinicalgenome.org/r/6bdd4757-0be0-4f8b-953f-c29e01591926"}],"detectionMethod":"The patient was genotyped by a targeted exome panel with 26 known PCD-linked genes and 284 other candidate genes, followed by confirmation with Sanger sequencing of PCR products.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"The patient was diagnosed with primary ciliary dyskinesia.","phenotypes":["obo:HP_0200109","obo:HP_0012263","obo:HP_0012257"],"previousTesting":true,"previousTestingDescription":"Previous testing was a targeted exome panel with 26 known PCD-linked genes and 284 other candidate genes.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/baffc33b-cbaf-493c-b778-6754335fd0d5_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/98b6c495-10fb-498f-92a9-2cb04e38d3e0_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b5801b89-46e7-4341-808a-4d5caf20ba71_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d774aa5-645a-4168-b5e1-c3f00a23d9ca","type":"EvidenceLine","dc:description":"The variant has been up-scored for its confirmed gene impact at the RNA level, but has been partially down-scored for its demonstrated origin as a founder variant (PMID: 16858015) and relatively high frequency in the control population from gnomAD.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d774aa5-645a-4168-b5e1-c3f00a23d9ca_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The NM_012144.4(DNAI1):c.48+2dup variant near the junction of exon 1 and intron 1 creates a cryptic splice donor site that triggers a 132bp in-frame insertion of sequence from intron 1 into the transcript (Fig. 7E from PMID: 10577904).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/9d774aa5-645a-4168-b5e1-c3f00a23d9ca_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21143860","allele":{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/94b984e9-05d0-4b1f-a5cd-05348f574ae9","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1612G>A (p.Ala538Thr) is a missense variant in exon 17 without experimental evidence of gene impact. It is a recurring variant detected in 5 apparently unrelated probands in this study and 2 more in PMID: 16858015, including on 2 different haplotypes. However, it has not been upscored due to its relatively high allele frequency in the control population.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94b984e9-05d0-4b1f-a5cd-05348f574ae9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21143860","allele":{"id":"https://genegraph.clinicalgenome.org/r/6189319f-6cf8-4a7a-a8c1-934867a8cd96"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/b5801b89-46e7-4341-808a-4d5caf20ba71","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21143860","rdfs:label":"ZiÄ™tkiewicz_2010_Family_161_Patient_124","allele":[{"id":"https://genegraph.clinicalgenome.org/r/6189319f-6cf8-4a7a-a8c1-934867a8cd96"},{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"}],"detectionMethod":"The patient was genotyped at the DNAI1 locus by SSCP of PCR products followed by Sanger sequencing. Multiplex ligation-dependent probe amplification analysis was subsequently performed to detect large exonic deletions.","firstTestingMethod":"SSCP","phenotypeFreeText":"The patient has been diagnosed with primary ciliary dyskinesia of the Kartagener syndrome subtype. Of cilia examined by electron microscope, 85% had outer or inner dynein arm defect, while 9% had a microtubule organization defect.","phenotypes":["obo:HP_0012263","obo:HP_0003363","obo:HP_0012256","obo:HP_0012257"],"previousTesting":false,"previousTestingDescription":"Previous testing was limited to clinical characterization of PCD.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/94b984e9-05d0-4b1f-a5cd-05348f574ae9_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/9d774aa5-645a-4168-b5e1-c3f00a23d9ca_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/ded2116e-df4f-43e1-a99c-80948c65b299_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a794ca7-4e20-4aec-a1a5-a55255d618f6","type":"EvidenceLine","dc:description":"The variant has been up-scored for its confirmed effect at the mRNA level but down-scored for its high frequency in the control population (consistent with its recurrence in multiple probands and evidence of a founder effect / shared haplotype).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a794ca7-4e20-4aec-a1a5-a55255d618f6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The NM_012144.4(DNAI1):c.48+2dup variant near the junction of exon 1 and intron 1 creates a cryptic splice donor site that triggers a 132bp in-frame insertion of sequence from intron 1 into the transcript (Fig. 7E from PMID: 10577904). Please note the relatively high frequency of this allele in the control population from gnomAD.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4a794ca7-4e20-4aec-a1a5-a55255d618f6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/af42e191-c002-489e-9946-918ca72f408f","type":"EvidenceLine","dc:description":"This variant has been up-scored for its confirmed effect at the mRNA level, but only conservatively due to the genotyping method (Sanger-based, focusing on the DNAI1 candidate locus).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/af42e191-c002-489e-9946-918ca72f408f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"While the nomenclature of the NM_012144.4(DNAI1):c.1490G>A (p.Gly497Asp) variant indicates a missense variant in exon 16, its location at a canonical splice site prompted an analysis of the paternal RNA showing that it triggers an abnormal splicing event (in-frame deletion of exons 15 and 16, so that this variant actually encodes p.Arg468_Lys523del, Figure 3A and 3B).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/af42e191-c002-489e-9946-918ca72f408f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/d447e7ca-5a60-46c3-8620-e71386a7ed19","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.1490G>A (p.Gly497Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA345040"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ded2116e-df4f-43e1-a99c-80948c65b299","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","rdfs:label":"Zariwala_2006_Patient_PCD930","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":10,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/d447e7ca-5a60-46c3-8620-e71386a7ed19"},{"id":"https://genegraph.clinicalgenome.org/r/936c4c89-7fb5-4e26-ae0e-838800fda03b"}],"detectionMethod":"The patient was genotyped at the DNAI1 locus by Sanger sequencing of PCR products from the 20 exons and associated flanking regions of the DNAI1 locus.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has been diagnosed with primary ciliary dyskinesia without Kartagener syndrome (implying absence of dextrocardia). Analysis of ciliary ultrastructure showed an outer dynein arm defect.","phenotypes":["obo:HP_0000246","obo:HP_0002643","obo:HP_0000388","obo:HP_0033036"],"previousTesting":false,"previousTestingDescription":"Previous testing was limited to clinical characterization of PCD.","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/af42e191-c002-489e-9946-918ca72f408f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/4a794ca7-4e20-4aec-a1a5-a55255d618f6_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/0c5e1af6-fa6e-4757-92a7-5b41cccf2509_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a0c4b55-7caf-4c11-93df-8e72051016bc","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1644G>A (p.Trp548Ter) is a nonsense variant in exon 17 of 20 that is predicted to trigger nonsense-mediated decay or to at least disrupt the C-terminal 22% of the protein product. Down-scoring has been performed to reflect the fact that the genotyping method was Sanger sequencing focused on the DNAI candidate locus.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a0c4b55-7caf-4c11-93df-8e72051016bc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/5d6f80e9-fdbd-405e-a079-2cb141f3ea7c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012144.4(DNAI1):c.1644G>A (p.Trp548Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5034487"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ba0ac747-2c1d-4215-b736-dbced7fd4514","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1612G>A (p.Ala538Thr) is a missense variant in exon 17, but does not have experimental evidence of gene impact. It has been observed in many apparently unrelated PCD probands with different variants in trans (one other in this study, as well as 5 in PMID: 21143860), including on two different haplotypes, but has been down-scored due to lack of functional evidence.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ba0ac747-2c1d-4215-b736-dbced7fd4514_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","allele":{"id":"https://genegraph.clinicalgenome.org/r/6189319f-6cf8-4a7a-a8c1-934867a8cd96"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/0c5e1af6-fa6e-4757-92a7-5b41cccf2509","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16858015","rdfs:label":"Zariwala_2006_Patient_PCD327","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/5d6f80e9-fdbd-405e-a079-2cb141f3ea7c"},{"id":"https://genegraph.clinicalgenome.org/r/6189319f-6cf8-4a7a-a8c1-934867a8cd96"}],"detectionMethod":"The patient was genotyped at the DNAI1 locus by Sanger sequencing of PCR products from the 20 exons and associated flanking regions of the DNAI1 locus.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has been diagnosed with the Kartagener syndrome subtype of primary ciliary dyskinesia (implying presence of dextrocardia). Analysis of ciliary ultrastructure showed an outer dynein arm defect.\n","phenotypes":["obo:HP_0001651","obo:HP_0000246","obo:HP_0002643"],"previousTesting":false,"previousTestingDescription":"Previous testing was limited to clinical characterization of PCD.","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/2a0c4b55-7caf-4c11-93df-8e72051016bc_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/ba0ac747-2c1d-4215-b736-dbced7fd4514_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/679b1cf3-c508-4417-a022-fac06029c577_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0053132a-30cd-4e52-b95e-a35e38be8542","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1212T>G (p.Tyr404Ter) is a nonsense variant in exon 13 of 20 and is predicted to trigger NMD or at least truncate ~42% of the protein product. It has been scored in this curation at reduced strength in another proband with a different variant in trans (PMID: 16858015).","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0053132a-30cd-4e52-b95e-a35e38be8542_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21270641","allele":{"id":"https://genegraph.clinicalgenome.org/r/45936e6d-21d5-4772-825b-859b68a927e6"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/a43201fc-0d81-4a14-adb1-573386543bb8","type":"EvidenceLine","dc:description":"NM_012144.4(DNAI1):c.1644G>A (p.Trp548Ter) is a nonsense variant in exon 15 of 20 and is predicted to trigger NMD or at least truncate ~22% of the protein product. It has been scored in this curation at reduced strength in another proband with a different variant in trans (PMID: 16858015).","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a43201fc-0d81-4a14-adb1-573386543bb8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21270641","allele":{"id":"https://genegraph.clinicalgenome.org/r/5d6f80e9-fdbd-405e-a079-2cb141f3ea7c"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/679b1cf3-c508-4417-a022-fac06029c577","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21270641","rdfs:label":"Berg_2011_Patient_1072","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/5d6f80e9-fdbd-405e-a079-2cb141f3ea7c"},{"id":"https://genegraph.clinicalgenome.org/r/45936e6d-21d5-4772-825b-859b68a927e6"}],"detectionMethod":"The patient was genotyped by exon-capture and massively parallel sequencing.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0033036","obo:HP_0200109","obo:HP_0000246","obo:HP_0000403","obo:HP_0002643"],"previousTesting":true,"previousTestingDescription":"Previous testing was limited to Sanger sequencing of the DNAI1 and DNAH5 loci.","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/a43201fc-0d81-4a14-adb1-573386543bb8_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/0053132a-30cd-4e52-b95e-a35e38be8542_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":4695,"specifiedBy":"GeneValidityCriteria9","strengthScore":17.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/4j04NIEfwtE","type":"GeneValidityProposition","disease":"obo:MONDO_0009484","gene":"hgnc:2954","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_396be572-5b2c-4859-90dd-434a91c1ce96-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}